VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
KEQU
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
KEQUKewaunee Scientific Corporation
$34.80$100M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksKEQUFinancials

Kewaunee Scientific Corporation (KEQU) Financials

30Y historyFree accessUpdated daily

Revenue growth remains highly volatile, with quarterly expansion rates fluctuating between 46.9% and 3.3%, while operating margins remain compressed at 3.7% as of 2026Q3.

KEQU Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricApr'26Apr'25Apr'24Apr'23Apr'22Apr'21Apr'20Apr'19Apr'18Apr'17Apr'16Apr'15Apr'14Apr'13Apr'12Apr'11Apr'10Apr'09Apr'08Apr'07Apr'06Apr'05Apr'04Apr'03Apr'02Apr'01Apr'00Apr'99Apr'98Apr'97
Sales/Revenue282M240.47M203.75M219.49M168.87M147.47M147.54M146.55M158.05M138.56M128.63M118.83M111.17M117.12M102.85M100M99.09M103.98M89.51M81.44M84.07M73.48M94.7M71.16M84.85M77.06M74.8M77.5M73M62M
Revenue Growth %17.27%18.02%-7.17%29.98%14.51%-0.05%0.68%-7.28%14.07%7.72%8.25%6.89%-5.08%13.88%2.84%0.92%-4.7%16.16%9.91%-3.13%14.41%-22.41%33.07%-16.13%10.11%3.02%-3.49%6.16%17.74%7.64%
Cost of Goods Sold201.56M171.62M151.7M183.91M144.65M123.48M124.11M121.23M126.03M111.95M104.92M97.06M89.13M94.86M83.69M80.72M77.69M82.61M70.34M66.36M71.66M61M79.01M58.45M70.14M60.38M55.75M58.2M54.3M46.5M
COGS % of Revenue71.48%71.37%74.45%83.79%85.66%83.73%84.12%82.72%79.74%80.8%81.57%81.68%80.18%81%81.37%80.72%78.4%79.44%78.58%81.48%85.24%83.01%83.43%82.14%82.67%78.35%74.53%75.1%74.38%75%
Gross Profit80.44M68.86M52.05M35.59M24.22M23.99M23.43M25.32M32.02M26.61M23.71M21.77M22.03M22.26M19.16M19.28M21.4M21.37M19.17M15.09M12.41M12.48M15.69M12.71M14.71M16.68M19.05M19.3M18.7M15.5M
Gross Margin %28.52%28.63%25.55%16.21%14.34%16.27%15.88%17.28%20.26%19.2%18.43%18.32%19.82%19%18.63%19.28%21.6%20.56%21.42%18.52%14.76%16.99%16.57%17.86%17.33%21.65%25.47%24.9%25.62%25%
Gross Profit Growth %16.82%32.29%46.26%46.94%0.95%2.42%-7.47%-20.93%20.34%12.23%8.92%-1.21%-1.02%16.19%-0.66%-9.9%0.14%11.48%27.08%21.58%-0.61%-20.43%23.42%-13.56%-11.86%-12.42%-1.29%3.21%20.65%25%
Operating Expenses63.73M51.1M33.77M30.22M26.83M25.31M25.77M23.21M22.93M20.07M18.01M16.54M16.07M16.98M16.44M16.13M15.58M14.29M13.56M11.73M11.29M12.7M13.49M13.48M11.8M12.16M14.4M13.9M14.4M13M
OpEx % of Revenue22.6%21.25%16.57%13.77%15.89%17.16%17.47%15.84%14.51%14.48%14%13.92%14.45%14.5%15.99%16.13%15.72%13.74%15.15%14.4%13.43%17.28%14.25%18.94%13.91%15.77%19.25%17.94%19.73%20.97%
Selling, General & Admin051.1M37.95M29.93M26.8M26.46M26.23M23.21M22.24M20.07M16.84M16.54M16.07M16.98M00014.29M13.56M11.73M12.18M12.7M13.49M13.48M11.8M12.16M12.43M12.3M13.1M11.5M
SG&A % of Revenue-21.25%18.62%13.64%15.87%17.94%17.78%15.84%14.07%14.48%13.09%13.92%14.45%14.5%---13.74%15.15%14.4%14.48%17.28%14.25%18.94%13.91%15.77%16.62%15.87%17.95%18.55%
Research & Development00920K1.01M990K1.41M1.82M1.55M1.54M1.16M1.17M936K842K872K0000000000000000
R&D % of Revenue--0.45%0.46%0.59%0.95%1.23%1.06%0.97%0.84%0.91%0.79%0.76%0.74%----------------
Other Operating Expenses63.73M51.1M-5.1M30.22M26.83M24.16M25.32M389K693K496K0484K395K306K16.44M16.13M15.58M000-884K000001.97M1.6M1.3M1.5M
Operating Income16.71M17.76M18.28M3.63M-2.61M-1.32M-2.35M2.11M9.09M6.54M5.7M5.23M5.96M5.28M2.71M3.16M5.83M7.08M5.61M3.36M1.12M-215K2.2M-764K2.9M2.36M4.65M5.4M4.3M2.5M
Operating Margin %5.93%7.39%8.97%1.65%-1.54%-0.89%-1.59%1.44%5.75%4.72%4.43%4.4%5.36%4.51%2.64%3.16%5.88%6.81%6.27%4.12%1.33%-0.29%2.32%-1.07%3.42%3.06%6.22%6.97%5.89%4.03%
Operating Income Growth %-5.88%-2.86%403.33%239.26%-98.18%43.88%-211.03%-76.76%38.89%14.81%9.03%-12.37%13.02%94.51%-14.06%-45.82%-17.74%26.21%67.15%200.63%619.53%-109.78%387.7%-126.3%23.09%-49.29%-13.81%25.58%72%150%
EBITDA21.47M22.52M21.41M6.5M161K1.37M309K4.68M11.85M9.24M8.29M7.84M8.51M7.93M5.38M5.64M8.18M9.35M7.59M5.31M3.14M1.83M4.25M1.54M5.08M4.53M6.62M7M5.6M4M
EBITDA Margin %7.61%9.36%10.51%2.96%0.1%0.93%0.21%3.2%7.5%6.67%6.44%6.6%7.66%6.77%5.23%5.64%8.25%8.99%8.48%6.52%3.74%2.49%4.48%2.17%5.98%5.88%8.85%9.03%7.67%6.45%
EBITDA Growth %-4.64%5.19%229.37%3936.65%-88.26%343.69%-93.4%-60.47%28.16%11.51%5.73%-7.89%7.35%47.48%-4.73%-30.96%-12.54%23.08%43.01%68.89%71.52%-56.83%175.18%-69.61%12.15%-31.62%-5.4%25%40%53.85%
D&A (Non-Cash Add-back)4.76M4.76M3.13M2.87M2.77M2.69M2.65M2.57M2.76M2.7M2.59M2.62M2.55M2.65M2.66M2.49M2.35M2.26M1.98M1.95M2.03M2.05M2.05M2.31M2.17M2.17M1.97M1.6M1.3M1.5M
EBIT16.71M18M14.92M5.29M-1.85M-2.23M-2.37M1.82M9.22M6.54M6.38M5.23M5.96M5.58M2.98M3.16M5.83M7.06M5.66M3.36M1.12M-215K2.2M-764K2.9M4.53M4.65M5.4M4.3M2.5M
Net Interest Income-3.86M-3.21M-1.8M-1.73M-632K-389K-493K-367K-299K-292K-306K-325K-373K-362K-445K-199K-157K-280K-294K00000000000
Interest Income000000000000000000000000000000
Interest Expense3.86M3.21M1.8M1.73M632K389K493K367K299K292K306K325K373K362K445K199K157K280K294K00000000000
Other Income/Expense-2.98M-2.97M-5.16M-866K123K-1.3M-521K22K-300K204K41K159K22K-56K-174K-195K-156K-308K-247K-617K-420K-308K18.09M-127K-212K-522K157K200K0-100K
Pretax Income13.73M14.79M13.12M4.5M-2.48M-2.62M-2.87M2.13M9.48M6.75M5.74M5.38M5.99M5.22M2.54M2.96M5.67M6.78M5.37M2.74M697K-523K20.28M-891K2.69M1.84M4.81M5.6M4.3M2.4M
Pretax Margin %4.87%6.15%6.44%2.05%-1.47%-1.77%-1.94%1.46%6%4.87%4.46%4.53%5.38%4.46%2.47%2.96%5.72%6.52%5.99%3.37%0.83%-0.71%21.42%-1.25%3.17%2.39%6.43%7.23%5.89%3.87%
Income Tax3.27M3.2M-5.94M3.14M3.52M990K1.76M446K4.12M2.13M1.86M1.75M1.98M1.54M739K864K1.92M2.26M1.73M902K288K-488K621K-549K793K561K1.25M2.2M1.7M100K
Effective Tax Rate %23.8%21.66%-45.26%69.79%-141.57%-37.83%-61.34%20.9%43.41%31.51%32.44%32.4%33.13%29.5%29.11%29.17%33.87%33.41%32.3%32.91%41.32%93.31%3.06%61.62%29.45%30.52%25.98%39.29%39.53%4.17%
Net Income9.62M11.4M18.75M1.36M-6M-3.61M-4.62M1.53M5.19M4.51M3.8M3.53M3.9M3.04M1.03M1.85M3.57M4.25M3.13M1.54M193K-147K1.46M-342K1.9M1.28M3.56M3.4M2.6M2.3M
Net Margin %3.41%4.74%9.2%0.62%-3.55%-2.45%-3.13%1.04%3.28%3.26%2.96%2.97%3.5%2.6%1%1.85%3.6%4.08%3.5%1.89%0.23%-0.2%1.54%-0.48%2.24%1.66%4.76%4.39%3.56%3.71%
Net Income Growth %-15.67%-39.18%1279.91%122.64%-66.43%21.99%-402.42%-70.53%14.91%18.75%7.74%-9.4%27.96%195.25%-44.27%-48.21%-15.89%35.51%103.51%697.93%231.29%-110.05%527.49%-118%48.79%-64.14%4.74%30.77%13.04%475%
Net Income (Continuing)10.46M11.58M19.06M1.36M-6M-3.61M-4.62M1.69M5.46M4.62M3.88M3.64M4M3.68M1.8M2.1M3.75M4.51M3.63M1.54M193K-35K1.46M-342K1.9M1.28M3.56M3.4M2.6M2.3M
Discontinued Operations000000000000000000000000000000
Minority Interest2.09M1.79M1.45M1.08M486K246K288K603K462K374K310K323K265K2.02M2.15M1.52M1.24M1.31M1.77M1.18M818K600K00000000
EPS (Diluted)3.223.836.380.47-2.15-1.31-1.680.551.871.661.421.331.481.170.400.721.391.661.230.620.08-0.060.59-0.140.770.511.441.381.060.96
EPS Growth %-15.93%-39.97%1257.45%121.86%-64.12%22.02%-405.45%-70.59%12.65%16.9%6.77%-10.14%26.5%192.5%-44.44%-48.2%-16.27%34.96%98.39%675%235.82%-109.98%521.43%-118.18%50.98%-64.58%4.35%30.19%10.42%540%
EPS (Basic)3.363.986.510.48-2.15-1.31-1.680.561.911.671.431.341.491.180.400.721.391.661.240.620.08-0.060.59-0.140.770.521.451.401.070.96
Diluted Shares Outstanding2.98M2.98M2.94M2.9M2.79M2.76M2.75M2.79M2.78M2.73M2.69M2.66M2.63M2.6M2.58M2.58M2.58M2.56M2.56M2.5M2.49M2.5M2.5M2.48M2.48M2.49M2.48M2.46M2.42M2.37M
Basic Shares Outstanding2.86M2.86M2.88M2.82M2.79M2.76M2.75M2.74M2.72M2.71M2.67M2.63M2.61M2.59M2.58M2.58M2.56M2.56M2.53M2.49M2.49M2.49M2.49M2.48M2.47M2.47M2.46M2.43M2.39M2.37M
Dividend Payout Ratio-------132.77%34.58%34.77%35.8%34.97%28.81%34%100%55.68%27.32%19.26%22.59%45.32%361.66%-47.61%-36.42%54.03%17.94%14.71%15.38%8.7%

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Project-based revenue lumpiness

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Volatile Revenue Growth Patterns Observed

As reported in recent financial filings, Kewaunee Scientific experienced significant revenue fluctuations, with quarterly growth rates swinging from a 46.9% expansion in 2026Q1 to a 3.3% increase by 2026Q3, highlighting the inherent instability of their project-based business model within the laboratory infrastructure sector.

The wide variance in quarterly revenue growth suggests that the company remains highly susceptible to the timing of large-scale construction milestones rather than consistent organic demand. Investors should monitor whether this volatility reflects genuine project delays or a broader cooling in the pharmaceutical and biotech capital expenditure cycles.

Structural Margin Sensitivity to Inputs

Based on the company's historical income statements, gross margins have fluctuated between 25.7% and 31.2%, indicating that Kewaunee Scientific's profitability is heavily tethered to raw material price volatility and the company's ability to pass through costs within its specialized laboratory furniture and fume hood segments.

The compression of gross margins toward the 26.7% level in 2026Q3 suggests that the company may be struggling to maintain pricing power against rising input costs or competitive bidding pressures. This margin profile warrants further investigation into whether the firm can successfully shift its product mix toward higher-complexity, proprietary safety equipment to insulate itself from commodity-linked furniture pricing.

Operating Leverage Remains Under Pressure

According to the provided quarterly data, operating income has failed to scale consistently with revenue, as evidenced by the 2026Q3 operating margin of 3.7% despite significant top-line activity, suggesting that the company's fixed-cost manufacturing footprint creates substantial operational drag during periods of lower project throughput.

The lack of clear operating leverage implies that Kewaunee Scientific has not yet achieved the necessary scale to decouple its overhead from its project-based revenue stream. Analysts should scrutinize whether the recent increase in SG&A expenses is a temporary investment in growth or a structural inefficiency that will continue to weigh on bottom-line profitability.

Earnings Quality Impacted by Volatility

Based on reported figures, net income has exhibited extreme variability, ranging from a high of $11.0 million in 2024Q4 to a low of $692,000 in 2026Q3, which suggests that non-operating items or project-specific accounting milestones may be significantly distorting the underlying earnings power of the business.

The sharp decline in EPS growth during recent quarters, despite revenue growth, indicates that investors should be cautious about relying on headline net income as a proxy for operational health. The presence of stock-based compensation, while relatively modest, further complicates the assessment of true cash-generative capacity for shareholders.

KEQU — Frequently Asked Questions

Quick answers to the most common questions about buying KEQU stock.

What was Kewaunee Scientific Corporation's (KEQU) revenue in 2026?

For fiscal year 2026, Kewaunee Scientific Corporation (KEQU) reported total revenue of $282.0M. This represents a 354.8% increase compared to $62.0M in 1997.

Is Kewaunee Scientific Corporation (KEQU) profitable?

Kewaunee Scientific Corporation (KEQU) is profitable, generating $9.6M in net income for the fiscal year ending 2026 with a net profit margin of 3.4%.

What is Kewaunee Scientific Corporation's operating profit margin?

Kewaunee Scientific Corporation (KEQU) reported an operating income of $16.7M, resulting in an operating profit margin of 5.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Kewaunee Scientific Corporation's gross profit and gross margin?

Kewaunee Scientific Corporation (KEQU) generated $80.4M in gross profit for the year, representing a gross profit margin of 28.5%. This demonstrates the company's core pricing power and production efficiency.